Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 9/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 5/20 | 0.33 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4070456 | 0.79 | MAPK14 (0.37) | MAPK14KMT2AMET | |
| Hydrochloric Acid SCHEMBL4083133 | 0.69 | MAPK14 (0.46) | MAPK14 | |
| SCHEMBL17221756 | 0.67 | ALDH1A1 (0.34) | KMT2A | |
| SCHEMBL4817084 | 0.66 | MAOA (0.45) | MAPK14MET | |
| SCHEMBL7424659 | 0.64 | PPARA (0.42) | GABRA1GABRG2GABRB3USP1WDR48 | |
| SCHEMBL7569928 | 0.64 | GABRA1 (0.38) | GABRA1GABRG2GABRB3USP1PPARA | |
| SCHEMBL24332597 | 0.63 | FLT1 (0.43) | MAPK14KMT2A | |
| Benzyl Alcohol SCHEMBL28599337 | 0.63 | TSHR (0.64) | GABRA1GABRG2GABRB3PPARAPPARG | |
| SCHEMBL23479734 | 0.63 | FFAR1 (0.52) | GABRA1GABRG2GABRB3PPARAPPARG | |
| SCHEMBL5766586 | 0.63 | MAPK14 (0.52) | MAPK14MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076356-B2 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors | PFIZER INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | PFIZER INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAPK14 24/4885GABRA1 3959/4885GABRG2 3965/4885 |
| US-20090239899-A1 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAPK14 24/4885GABRA1 4018/4885GABRG2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.